MLL gene rearrangement affects 5-10% of all patients with T-ALL, but the ability of these rearrangements to independently predict patient minimum residual disease (MRD) outcomes at the end of consolidation therapy has yet to be confirmed (8). Here, KMT2A is linked to acute lymphoblastic leukemia.